Document Detail

Systematic survey of variants in TBX1 in non-syndromic tetralogy of Fallot identifies a novel 57 base pair deletion that reduces transcriptional activity but finds no evidence for association with common variants.
Jump to Full Text
MedLine Citation:
PMID:  20937753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Tetralogy of Fallot (TOF) is common in individuals with hemizygous deletions of chromosome 22q11.2 that remove the cardiac transcription factor TBX1.
OBJECTIVE: To assess the contribution of common and rare TBX1 genetic variants to TOF.
DESIGN: Rare TBX1 variants were sought by resequencing coding exons and splice-site boundaries. Common TBX1 variants were investigated by genotyping 20 haplotype-tagging SNPs capturing all the common variations present at the locus. Association analysis was performed using the program UNPHASED.
PATIENTS: TBX1 exons were sequenced in 93 patients with non-syndromic TOF. Single nucleotide polymorphism analysis was performed in 356 patients with TOF, their parents and healthy controls.
RESULTS: Three novel variants not present in 1000 chromosomes from healthy ethnically matched controls were identified. One of these variants, an in-frame 57 base-pair deletion in the third exon which removed 19 evolutionarily conserved residues, decreased transcriptional activity by 40% in a dual luciferase assay (p=0.008). Protein expression studies demonstrated that this mutation affected TBX1 protein stability. After correction for multiple comparisons, no significant associations between common genetic variants and TOF susceptibility were found.
CONCLUSION: This study demonstrates that rare TBX1 variants with functional consequences are present in a small proportion of non-syndromic TOF.
Authors:
Helen R Griffin; Ana Töpf; Elise Glen; Christiane Zweier; A Graham Stuart; Jonathan Parsons; Ian Peart; John Deanfield; John O'Sullivan; Anita Rauch; Peter Scambler; John Burn; Heather J Cordell; Bernard Keavney; Judith A Goodship
Related Documents :
16287113 - High proportion of large genomic stk11 deletions in peutz-jeghers syndrome.
7945303 - Deletion of exon 18 is a frequent mutation in glycogen storage disease type ii.
24294103 - Wild mice as bountiful resources of novel genetic variants for quantitative traits.
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Heart (British Cardiac Society)     Volume:  96     ISSN:  1468-201X     ISO Abbreviation:  Heart     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-12     Completed Date:  2011-05-02     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  9602087     Medline TA:  Heart     Country:  England    
Other Details:
Languages:  eng     Pagination:  1651-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Base Pairing / genetics
Case-Control Studies
Chromosome Deletion*
Genetic Predisposition to Disease
Genotype
Humans
Polymorphism, Single Nucleotide
T-Box Domain Proteins / genetics*,  metabolism
Tetralogy of Fallot / genetics*,  metabolism
Transcriptional Activation
Grant Support
ID/Acronym/Agency:
RG/02/014//British Heart Foundation; RG/08/012/25941//British Heart Foundation; //Medical Research Council
Chemical
Reg. No./Substance:
0/T-Box Domain Proteins; 0/TBX1 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Heart
Journal ID (publisher-id): heart
Journal ID (hwp): heartjnl
ISSN: 1355-6037
ISSN: 1468-201X
Publisher: BMJ Group, BMA House, Tavistock Square, London, WC1H 9JR
Article Information
Download PDF
© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
open-access:
Accepted Day: 30 Month: 6 Year: 2010
Electronic publication date: Day: 11 Month: 10 Year: 2010
Print publication date: Day: 15 Month: 10 Year: 2010
pmc-release publication date: Day: 11 Month: 10 Year: 2010
Volume: 96 Issue: 20
First Page: 1651 Last Page: 1655
PubMed Id: 20937753
Publisher Id: heartjnl200121
DOI: 10.1136/hrt.2010.200121

Systematic survey of variants in TBX1 in non-syndromic tetralogy of Fallot identifies a novel 57 base pair deletion that reduces transcriptional activity but finds no evidence for association with common variants
Helen R Griffin1
Ana Töpf1
Elise Glen1
Christiane Zweier2
A Graham Stuart3
Jonathan Parsons4
Ian Peart5
John Deanfield6
John O'Sullivan7
Anita Rauch28
Peter Scambler9
John Burn1
Heather J Cordell1
Bernard Keavney1
Judith A Goodship1
1Institute of Human Genetics, Newcastle University, Newcastle-upon-Tyne, UK
2Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
3Bristol Children's Hospital, Bristol, UK
4Leeds General Infirmary, Leeds, UK
5Alder Hey Hospital, Liverpool, UK
6Great Ormond Street Hospital, London, UK
7Freeman Hospital, Newcastle-upon-Tyne, UK
8Institute of Medical Genetics, University of Zurich, Schwerzenbach-Zurich, Switzerland
9Institute of Child Health, London, UK
Correspondence: Correspondence to Dr Judith Goodship, Institute of Human Genetics, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK; j.a.goodship@ncl.ac.uk

Introduction

Congenital heart defects (CHD) occur in approximately seven out of every 1000 live births.1 Tetralogy of Fallot (TOF), which accounts for approximately 7% of CHD and is the commonest cyanotic CHD,2 occurs in a number of syndromes but in the majority of cases is an isolated defect. Chromosome 22q11.2 deletions account for approximately 7% of TOF cases3, 4 and trisomy 21 accounts for a further 5% of cases.3 A rarer syndromic association is Alagille syndrome which results from JAG1 haploinsufficiency or intragenic mutation. The advent of array-based molecular karyotyping has shown that approximately another 10% of cases are the result of copy number variants.5 However, around 75% of cases are unexplained and are thought to result from a complex interaction of environmental and genetic factors. In support of this model, substantial genetic influences have been inferred for certain malformations in studies of familial recurrence risk ascertained through non-syndromic patients.6 A CHD risk of 3.1% in offspring and 2.2% in siblings of patients with TOF has been reported, indicating a substantial increase in CHD risk for first-degree relatives of cases compared with the general population.6

CHD is common in patients with chromosome 22q11.2 deletion, with 17% of patients with 22q11.2 deletions having TOF.7 The deletion, which is mediated by non-homologous recombination between low copy repeats, typically removes a genomic segment including the cardiac transcription factor TBX1. TBX1-expressing progenitors contribute to the majority of the outflow tract (OFT) and right ventricle of the developing heart.8–13 Studies in mouse models have shown that Tbx1 deletions or null mutations in the mouse cause CHD including OFT lesions.8, 10, 14, 15 Human studies have identified nine novel variants of TBX1 that alter protein sequence in patients who have clinical features of the 22q11.2 deletion syndrome, including CHD, but who do not carry a chromosomal microdeletion.16–19 Some of these mutations completely ablate TBX1 function in vitro, while others result in a gain of TBX1 function, suggesting an optimal range of TBX1 activity above or below which the risk of malformations increases.

We hypothesised that hypomorphic alleles of TBX1 which reduce but do not completely ablate TBX1 function, might be involved in susceptibility to non-syndromic TOF. Variants affecting TBX1 expression levels and thus potentially predisposing to TOF risk, could be rare or common; no previous study has investigated the role of common single nucleotide polymorphisms (SNPs) in the TBX1 gene in TOF susceptibility. In this study, we screened patients with non-syndromic TOF for rare genetic variants in all coding exons of TBX1 by resequencing and performed association analysis of common haplotype-tagging SNPs (htSNPs) in and around TBX1 in trio families, cases and controls.


Material and methods
Study population

Patients with TOF, of White European ancestry, were recruited from four UK paediatric cardiology centres. Clinical records were reviewed before recruitment, and probands with known chromosomal abnormalities, other recognised syndromes, learning difficulties, or known maternal exposure to significant teratogens during pregnancy were excluded. Parental samples were obtained where possible. Proband samples were screened for 22q11.2 deletion by multiplex ligation-dependent probe amplification (MRC-Holland, Amsterdam, Netherlands), and samples with deletions were excluded from further analysis. Ethical approval was given for the study and fully informed consent was obtained from all participants (or their parents, if children were too young to themselves consent). DNA was extracted from blood or saliva samples using standard protocols.

Exon sequencing

TBX1 coding sequence and consensus splice sites were sequenced in 93 unrelated TOF probands. Intronic PCR primers were designed based on transcripts NM_080646, NM_005992 and NM_080647 (www.ncbi.nlm.nih.gov, accessed 26 July 2010). PCR products were cleaned before bi-directional dideoxy sequencing and sequence traces analysed using the Staden Package suite of programs (http://staden.sourceforge.net/, accessed 26 July 2010). Previously unreported variants found in the TOF probands were genotyped in 1000 control chromosomes.

Constructs and luciferase assays

The TBX1 variants c.115G→A and c.129_185del57 were introduced into the TBX1 expression construct TBX1-pcDNA318 by site-directed mutagenesis. TBX1 constructs were transfected into U2-OS cells along with pGL2tk-2xT, which contains two copies of the T-binding site adjacent to firefly luciferase,19 and Renilla luciferase control. RNA was extracted from transfected cells using standard techniques, DNAase treated to avoid amplification of remaining transfected plasmid and Taqman relative-quantification real-time PCR (Applied Biosystems, California, USA) performed to check that equivalent levels of transcript were obtained for TBX1 and the TBX1 variants. The transcriptional activity of TBX1 and the TBX1 variants was then measured by comparison of the firefly luciferase reading with the Renilla luciferase control (dual luciferase assay).

Immunocytochemistry

HEK293 cells were seeded on glass cover slips and transfected with wild-type or variant TBX1. Twenty-four hours after transfection, cells were fixed, permeabilised with 0.1% Triton X-100 in phosphate-buffered saline (PBS) and after blocking with 5% goat serum in PBST probed with rabbit anti-Tbx1 antibody (Zymed) followed by the secondary antibody (Cy3 conjugated sheep anti-rabbit antibody, Sigma). Cells were mounted with VectaShield containing 4,6-diamino-2-phenylindole.

Protein expression and stability

The stability of the p.Pro43_Pro61del variant protein was compared with the wild-type protein using cycloheximide inhibition of de novo protein synthesis followed by western blot analysis. HEK293 cells were transfected with wild-type or variant TBX1. Twenty-four hours after transfection, cells were treated with 25 μg/ml cycloheximide and lysed at 2 h intervals using 2X sodium dodecyl sulphate denaturing buffer (0.5 M Tris pH 6.8, 4% sodium dodecyl sulphate (w/v), 20% glycerol, 1.5% dithiothreitol (w/v)). Proteins were resolved on a 12% polyacrylamide gel and transferred onto Hybond ECL membrane (GE, Buckinghamshire, UK). Membranes were probed with anti-Tbx1 antibody (Zymed) and anti-nucleolin antibody (Bethyl, Montgomery, TX, USA) as a loading control then detected with horseradish peroxidase-conjugated anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA, USA) using West Dura ECL kit (Thermoscientific, Rockford, IL, USA). Band intensities were measured in Adobe Photoshop, normalising TBX1 expression to the loading control.

SNP genotyping

Three hundred and fifty-six patients with TOF, comprising 203 parent–child trios, 80 parent–child duos, 67 singleton probands and six probands from three multiplex families were genotyped. One hundred and eighty-two unrelated healthy individuals, free of CHD, of White European ancestry were also genotyped as controls for those cases where family members were not available. Sixteen htSNPs were selected from 15 kb upstream of TBX1 to 4.5 kb downstream of TBX1 using the HapMap data for the samples of Northern and Western European ancestry (CEU samples; http://www.hapmap.org, accessed 27 July 2010) and the Tagger utility of Haploview v3.2 (http://www.broad.mit.edu/mpg/haploview, accessed 27 July 2010). These htSNPs had a minor allele frequency >0.05 and were in linkage disequilibrium at r2 >0.8 with all other genetic variations within the region. Four additional SNPs (rs5748418, rs737868, rs13054377 and c.1189A→C), which were identified by sequencing of the TOF cases and which were not in linkage disequilibrium (R2<0.8) with the selected ht SNPs, were also included.

Statistical analysis

Luciferase activation by control and mutant TBX1 proteins and mRNA production from the different TBX1 constructs in cell culture, were compared using paired t tests. TBX1 wild-type and the p.Pro43_Pro61del variant protein concentration after cycloheximide treatment was analysed using analysis of variance (assuming a general linear model) and regression analysis in Minitab 15. Genotype data were checked for Mendelian consistency within the families and for Hardy–Weinberg equilibrium using PEDSTATS.20 Association analysis of the SNP genotypes within the families and unrelated controls was performed using UNPHASED version 3.0.9.21 UNPHASED was chosen in view of the program's capacity to handle datasets including both trio families and unrelated cases and controls and carry out genotype and haplotype association tests yielding p values for the entire dataset.


Results
Sequencing TBX1 in probands

Sequencing 93 TOF probands identified four previously unreported genetic variants present in eight probands. Three novel variants (c.115G→A, c.129_185del57 and c.1074G→A), were each present in one proband and absent from 1000 control chromosomes. The single-base substitution c.115G→A, resulting in a p.Gly39Ser amino acid substitution in exon 3 of TBX1, was inherited from a phenotypically normal mother. The patient with the 57 bp deletion (c.129_185del57) resulting in the in-frame amino acid deletion p.Pro43_Pro61del was noted to have a right-sided aortic arch. He inherited the change from his mother who has no history of congenital heart disease. A synonymous base substitution c.1074G→A was present in the exon 9C major isoform (NM_080647 isoform C) of a third proband and was also inherited from a phenotypically normal mother. The fourth previously unreported variant was a synonymous base substitution c.75G→T, p.Gly25Gly, present in five probands and seen in 20 of 1000 control chromosomes. These synonymous variants were thought unlikely to be causative and were not investigated further.

The glycine of the assumed amino acid substitution p.Gly39Ser is conserved in chimpanzee, rat, mouse and opossum (Monodelphis domestica) but is substituted by serine in the frog (Xenopus tropicalis and Xenopus laevis) and fish (Tetraodon nigrovirdis and Danio rerio). The sequence of the assumed 19 amino acid deletion p.Pro43_Pro61del shows a high degree of conservation in rat, mouse and opossum. The p.Pro52, p.Cys53 and p.Ala55 residues were also completely conserved in platypus (Ornithorhynchus anatinus), frog and fish.

Functional investigation of novel TBX1 variants

The mRNA expression of the wild-type construct and the two constructs incorporating mutations that changed the amino acid sequence (c.115G→A and c.129_185del57) was shown to be equal by relative quantification real-time PCR (p>0.05; data not shown). In the dual luciferase assay, the p.Gly39Ser TBX1 protein showed no significant difference in transcriptional activity from wild-type TBX1 (p=0.23; figure 1). The p.Pro43_Pro61del TBX1 protein, however, showed a significant 40% reduction in transcriptional activity compared with wild-type TBX1 (p=0.008; figure 1). Immunocytochemistry demonstrated that both the p.Gly39Ser mutated protein (not shown) and the 19 amino acid deleted protein locate to the nucleus, indicating that these mutations do not perturb protein localisation (figure 2). We next assessed the stability of the protein expressed from the c.129_185del57 TBX1 construct. There was no significant difference in the basal level of TBX1 protein expressed in cells transfected with the wild-type TBX1 or mutated TBX1 construct in three independent experiments (p=0.549). There was a significant difference in the rate at which intracellular TBX1 levels decreased after treatment with cycloheximide with the mutant protein being less stable in three independent experiments (p=0.003; figure 3).

Association analysis of htSNPs

The founder genotypes for all 20 TBX1 htSNPs were shown to be in Hardy–Weinberg equilibrium (p>0.01). Genotype and haplotype frequencies were in good agreement with HapMap data, for those markers where it was available. The likelihood ratio statistics and associated p values from the UNPHASED genotype analysis of the 20 TBX1 htSNPs in the TOF families and controls are shown in table 1. Three SNPs (rs739374, rs6518580 and rs5993820) showed borderline significant association (p=0.016–0.025) with TOF in 356 cases. However, this seems unlikely to reflect true association as these results do not withstand correction for multiple testing.


Discussion

We have carried out a comprehensive analysis of both common and rare TBX1 genetic variation in patients with non-syndromic TOF. Sequencing TBX1 exonic and splice site regions identified four previously unreported coding variants; three of which (c.115G→A, c.129_185del57 and c.1074G→A) were not present in 1000 control chromosomes. The c.129_185del57 variant, which deletes 19 evolutionarily conserved amino acids, was found to reduce the transcriptional activity of TBX1 by 40%. The decreased transcriptional activation observed supports our a priori hypothesis that if among the developmental processes perturbed by 22q11.2 deletion, normal cardiovascular development is particularly susceptible to differences in TBX1 activity, then hypomorphic alleles may confer risk of non-syndromic CHD. As the p.Pro43_Pro61 deletion is outside the DNA binding domain, which extends from aa119 to aa297, we next assessed whether subcellular localisation or protein stability were affected by the mutation. We found that the mutant protein localised appropriately to the nucleus but that it was less stable than wild-type protein. Thus a mechanism by which it leads to decreased transcriptional activity is that TBX1 protein levels are diminished, though this may not be the sole mechanism—for example, the deletion may also affect dimerisation or interaction with other partners. It is interesting that in addition to TOF this child also had a right-sided aortic arch, an abnormality reported in Tbx1 mutant mice.13 The c.115G→A, p.Gly39Ser variant did not affect transcriptional activity in the in vitro assay; however, this assay does not fully recapitulate the complex interactions occurring in the developing embryo. Transcription factors act on target genes in concert and as more becomes known about TBX1 protein interactions the effect of this mutation on protein interactions should be investigated. As yet, little is known about Tbx1 protein interactions but Tbx1 has recently been shown to interact with Srf (serum response factor), a regulator of muscle differentiation,22 and with SMAD1, affecting BMP signalling in a transcription independent manner.23

Although TBX1 mutations had been identified in studies of patients who have clinical features of chromosome 22q11.2 deletion syndrome, including CHD, but who are not deleted for the region,16–19 early studies of TBX1 in non-syndromic TOF were small and failed to identify mutations. A substantially larger recent study of 191 patients with TOF who did not have a chromosomal abnormality or recognised syndrome identified two novel TBX1 variants.3 One of these p.Pro290Ser, not present in 174 control individuals and inherited from a phenotypically normal father, did not affect transcriptional activity in vitro. The second, a 30 bp insertion, leading to expansion of a polyalanine tract, decreased transcriptional activity in vitro; further studies showed aggregation of the expressed mutant protein in the cytoplasm. Taking the two studies together it is evident that TBX1 coding sequence mutations do occur in patients with non-syndromic TOF but account for only about 1% of cases.

A recent study has demonstrated a non-linear relationship between Tbx1 mRNA dosage and the 22q11.2 deletion syndrome phenotype, including cardiac OFT defects, in the mouse.24 The penetrance of cardiac OFT defects was shown to sharply increase at mRNA concentrations of less than about 20% of normal in that study; the equivalent threshold for TBX1 activity in man is unknown, although our study suggests that human OFT development is sensitive to smaller decreases in TBX1 activity. In vitro studies of three TBX1 missense changes identified in patients with the 22q11.2 phenotype found increased transcriptional activity.19 Similarly, investigation of a 5′ untranslated change, -39C→T, identified in patients with the 22q11.2 phenotype showed this to be associated with increased transcript levels.16, 25 Thus human OFT development appears to be sensitive to decreased activity and also to increased TBX1 activity.

Systematic study of all common variation in the TBX1 region in 356 TOF cases, together with available parents and unrelated controls, provided no support for the hypothesis that common SNPs in this region have sizeable effects (ie, conferring ORs >2.0) on the risk of TOF, although the possibility smaller effects of common variants cannot be ruled out. No previous studies have investigated the potential contribution of common TBX1 genetic variants in TOF. For common conditions such as coronary disease, the contribution of SNPs to risk, discovered by genome-wide association studies, has been small, with ORs generally <1.3. However, some rarer diseases have been shown to be influenced to a greater extent by common variants. For example, Crohn's disease has a population prevalence approximately equal to that of congenital heart disease. SNPs in the Nod2/CARD15 gene with minor allele frequency ∼0.05 are associated with Crohn's disease risks of 2.2–4.0 to heterozygotes and around 17.0 to homozygotes26; this study had >80% power at p<10-5 to detect CHD risks of this magnitude associated with SNPs of similar frequency. Previous studies suggesting an oligogenic aetiology for TOF increased the a priori likelihood that effects of this size might be present.6 We had low power to detect common variants associated with relative risks <2.0 and larger studies will be required to conclusively establish the presence or absence of such smaller effects at TBX1. More generally, genome-wide association studies in large numbers of patients and family-based or unrelated controls will be required to resolve whether common genetic variation importantly influences non-syndromic CHD susceptibility.

In summary, this study is the first comprehensive investigation of common and rare TBX1 genetic variants in non-syndromic TOF cases. It has identified a rare novel functional genetic variant that is a likely susceptibility factor to TOF. However, as the study indicates that mutations in TBX1 account for at most a few per cent of the susceptibility to non-syndromic TOF it does not support the introduction of TBX1 mutation analysis to clinical practice in this patient group; systematic large-scale surveys of other CHD candidate genes will be necessary to identify the genetic risk factors accounting for the bulk of the heritability seen in epidemiological studies.


Notes

Funding: This work was supported by the British Heart Foundation (RG/02/014); European Community's Sixth Framework Programme contract ('HeartRepair') (LSHM-CT-2005-018630); and the Federated Foundation; BK holds a British Heart Foundation Chair; HRG was supported by a Medical Research Council PhD studentship.

Competing interests: None.

Patient consent: Obtained.

Provenance and peer review: Not commissioned; externally peer reviewed.

The principal acknowledgement is to the patients and families who participated in this study. We thank study nurses K Ashcroft, L Sneddon, C Roberts, J Peters, H Walker and R Hussein for technical support.


References
1. Hoffman JI,Kaplan S. The incidence of congenital heart disease. J Am Coll CardiolYear: 2002;39:1890–90012084585
2. Goldmuntz E. The epidemiology and genetics of congenital heart disease. Clin PerinatolYear: 2001;28:1–1011265502
3. Rauch R,Hofbeck M,Zweier C,et al. Comprehensive genotype-phenotype analysis in 230 patients with Tetralogy of Fallot. J Med GenetYear: 2009;47:321–3119948535
4. van Engelen K,Topf A,Keavney BD,et al. 22q11 Deletions in adults with Tetralogy of Fallot are highly under recognized. HeartYear: 2010;96:621–420357389
5. Greenway SC,Pereira AC,Lin JC,et al. De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat GenetYear: 2009;41:931–519597493
6. Burn J,Brennan P,Little J,et al. Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. LancetYear: 1998;351:311–169652610
7. Ryan AK,Goodship JA,Wilson DI,et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med GenetYear: 1997;34:798–8049350810
8. Lindsay EA,Vitelli F,Su H,et al. Tbx1 haploinsufficieny in the DiGeorge syndrome region causes aortic arch defects in mice. NatureYear: 2001;410:97–10111242049
9. Maeda J,Yamagishi H,McAnally J,et al. Tbx1 is regulated by forkhead proteins in the secondary heart field. Dev DynYear: 2006;235:701–1016444712
10. Merscher S,Funke B,Epstein JA,et al. TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. CellYear: 2001;104:619–2911239417
11. Vitelli F,Morishima M,Taddei I,et al. Tbx1 mutation causes multiple cardiovascular defects and disrupts neural crest and cranial nerve migratory pathways. Hum Mol GenetYear: 2002;11:915–2211971873
12. Xu H,Morishima M,Wylie JN,et al. Tbx1 has a dual role in the morphogenesis of the cardiac outflow tract. DevelopmentYear: 2004;131:3217–2715175244
13. Zhang Z,Cerrato F,Xu H,et al. Tbx1 expression in pharyngeal epithelia is necessary for pharyngeal arch artery development. DevelopmentYear: 2005;132:5307–1516284121
14. Jerome LA,Papaioannou VE. DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nat GenetYear: 2001;27:286–9111242110
15. Kimber WL,Hsieh P,Hirotsune S,et al. Deletion of 150 kb in the minimal DiGeorge/velocardiofacial syndrome critical region in mouse. Hum Mol GenetYear: 1999;8:2229–3710545603
16. Gong W,Gottlieb S,Collins J,et al. Mutation analysis of TBX1 in non-deleted patients with features of DGS/VCFS or isolated cardiovascular defects. J Med GenetYear: 2001;38:E4511748311
17. Yagi H,Furutani Y,Hamada H,et al. Role of TBX1 in human del22q11.2 syndrome. LancetYear: 2003;362:1366–7314585638
18. Paylor R,Glaser B,Mupo A,et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci U S AYear: 2006;103:7729–3416684884
19. Zweier C,Sticht H,Aydin-Yaylagul I,et al. Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions. Am J Hum GenetYear: 2007;80:510–1717273972
20. Wigginton JE,Abecasis GR. PEDSTATS: descriptive statistics, graphics and quality assessment for gene mapping data. BioinformaticsYear: 2005;21:3445–715947021
21. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum HeredYear: 2008;66:87–9818382088
22. Chen L,Fulcoli FG,Tang S,et al. Tbx1 regulates proliferation and differentiation of multipotent heart progenitors. Circ ResYear: 2009;105:842–5119745164
23. Fulcoli FG,Huynh T,Scambler PJ,et al. Tbx1 regulates the BMP-Smad1 pathway in a transcription independent manner. PLoS OneYear: 2009;4:e604919557177
24. Zhang Z,Baldini A. In vivo response to high-resolution variation of Tbx1 mRNA dosage. Hum Mol GenetYear: 2008;17:150–717916582
25. Torres-Juan L,Rosell J,Morla M,et al. Mutations in TBX1 genocopy the 22q11.2 deletion and duplication syndromes: a new susceptibility factor for mental retardation. Eur J Hum GenetYear: 2007;15:658–6317377518
26. Economou M,Trikalinos TA,Loizou KT,et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J GastroenterolYear: 2004;99:2393–40415571588

Figures

[Figure ID: fig1]
Figure 1 

Transcriptional activation of a luciferase reporter by wild-type (WT) and mutant TBX1. Wild type TBX1-pcDNA3 construct activates transcription, as does the G39S missense construct (c.115G→A), whereas the c.129_185del57 construct, resulting in an in-frame 19 amino acid deletion (p.Pro43_Pro61del) shows a significantly reduced transcriptional activity compared with the wild-type (40%, p=0.008). Results were normalised to Renilla luciferase for transfection efficiency and to pcDNA3 and are expressed as average values ± SD of three replicates. Results were confirmed in another three independent assays, all showing significant p values (0.002–0.02).



[Figure ID: fig2]
Figure 2 

Subcellular localisation of TBX1 wild-type and mutant protein in transiently transfected HEK293 cells stained with 4,6-diamino-2-phenylindole (DAPI) and analysed by immunocytochemistry with anti-Tbx1 antibody.



[Figure ID: fig3]
Figure 3 

(A) Representative western blot showing TBX1 protein expression after 0–6 h cycloheximide treatment in HEK293 cells transfected with either the wild-type (WT) TBX1-pcDNA3 construct or the c.129_185del57 TBX1-pcDNA3 construct. The 19 amino acid deletion in the p.Pro43_Pro61del TBX1 protein results in the smaller protein size detected in these samples. Both bands were TBX1-specific (checked using an empty pcDNA3 transfected control, data not shown). The upper TBX1 band for both wild-type and p.Pro43_Pro61del samples is believed to result from phosphorylation or other post-translational modification of TBX1 as the lower band is of the expected size for wild-type TBX1 isoform C (∼56 kDa). (B) Scatter plot showing TBX1 protein expression normalised to nucleolin (loading control) for three independent experiments 0–6 h after cycloheximide treatment of cells transfected with the wild-type TBX1 construct (full squares) compared with cells transfected with the c.129_185del57 TBX1 construct (open circles). Regression analysis of the three replicates describes the slopes of the lines; −4.6% (wild-type TBX1) and −17.8% (p.Pro43_Pro61del TBX1), as significantly different (p=0.003).



Tables
[TableWrap ID: tbl1] Table 1 

Association analysis of TBX1 genotypes


SNP TOF (356)
LR p Value
rs885988 5.195 0.074
rs7293017 1.077 0.584
rs739374 8.284 0.016*
rs8135854 4.011 0.135
rs6518580 7.352 0.025*
rs16984141 1.845 0.397
rs7291533 0.914 0.633
rs5993820 8.079 0.018*
rs1005133 1.672 0.434
rs4819520 1.726 0.422
rs5748418 1.719 0.423
rs737868 0.718 0.698
rs2301558 0.530 0.767
rs13054377 3.683 0.159
1189CA 1.553 0.460
rs2238777 0.892 0.640
rs4819522 0.121 0.941
rs5746826 2.851 0.240
rs5748425 0.097 0.953
rs5748427 0.173 0.917

Likelihood ratio (LR) χ2 statistics with nominal uncorrected associated probabilities (p value) for ‘UNPHASED’ analysis of TBX1 genotypes in the 356 TOF families.

*p Values <0.05.

SNP, single nucleotide polymorphism; TOF, tetralogy of Fallot.



Article Categories:
  • Congenital Heart Disease
Article Categories:
  • 1506

Keywords: TBX1, heart defects, congenital, tetralogy of Fallot, genetic association studies, mutation, genetics.

Previous Document:  What is the impact of providing a transcatheter aortic valve implantation service on conventional ao...
Next Document:  Cardiac outcomes after pregnancy in women with congenital heart disease.